Skip to main content
TipRanks
Go Ultimate75% OFF

AFC-HD AMS Life Science Co., Ltd. (2927) AI Stock Analysis

0 Followers
JP:2927

AFC-HD AMS Life Science Co., Ltd.

(TSE/TYO:2927)

Select Model
Rating:62Neutral
Price Target:JPY 893.00â–²(6.95% Upside)
Action:reiterated
Date:10/16/26

The overall score of 62 is anchored by the company's highly attractive valuation and strong dividend yield, which are heavily offset by persistent negative free cash flows, high leverage, and bearish technical momentum.

Positive Factors
Steady Revenue GrowthConsistent multi-year revenue expansion indicates sustained demand for the company’s health-related products and commercial offerings. Continued top-line growth can support operating scale, fund product development, and reinforce the company’s market position over the next several quarters.
Negative Factors
Weak Free Cash FlowPersistent negative free cash flow means reported earnings have not consistently converted into cash after investment needs. This can restrict internally funded growth, reduce capital-allocation flexibility, and make the company more dependent on balance-sheet resources while debt remains substantial.

AFC-HD AMS Life Science Co., Ltd. (2927) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%JP:2927+2.15%EWJ+14.66%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 12.16B
Dividend Yield
4.79%
Average Volume (3M)
25.29K
Price to Earnings (P/E)
10.1
Beta (1Y)
0.31
Revenue Growth
5.11%
EPS Growth
-19.41%
Country
Japan
Employees
1,008
Sector
Consumer Defensive
Sector Strength
62
Industry
Packaged Foods

AFC-HD AMS Life Science Co., Ltd. Business Overview & Revenue Model

Company Description

AFC-HD AMS Life Science Co., Ltd. operates as an original equipment manufacturer of health foods and cosmetics. The company operates through five segments: Healthcare, Pharmaceutical, Department Store, Food and Beverage, and Other Business. The Healt...

How the Company Makes Money

The company primarily makes money by selling health-related products (e.g., supplements and other wellness products) through its commercial channels. Revenue is generated from product sales, which may include (1) branded product sales to consumers an...

AFC-HD AMS Life Science Co., Ltd. Financial Statement Overview

Summary

Financial health is mixed. The company exhibits consistent top-line expansion, but is weighed down by declining net income, thin profit margins, elevated leverage (1.44 debt-to-equity), and persistent negative free cash flows.

Income Statement

72Positive

Balance Sheet

58Neutral

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMAug 2026Aug 2025Aug 2024Aug 2023Aug 2022
Income Statement
Total Revenue34.32B34.32B32.66B30.19B25.58B23.00B
Gross Profit11.65B11.65B10.97B10.49B9.32B8.58B
EBITDA3.98B3.92B3.80B3.10B2.59B2.30B
Net Income1.20B1.20B1.45B1.25B1.10B735.35M
Balance Sheet
Total Assets49.05B49.05B48.73B47.03B41.07B37.35B
Cash, Cash Equivalents and Short-Term Investments9.76B9.76B11.30B12.17B11.18B10.38B
Total Debt23.41B23.41B24.14B23.40B19.59B17.24B
Total Liabilities32.61B32.61B33.53B33.07B27.91B24.90B
Stockholders Equity16.21B16.21B15.08B13.93B13.11B12.44B
Cash Flow
Free Cash Flow0-726.43M-1.75B-1.87B-1.07B534.45M
Operating Cash Flow01.68B1.79B1.54B865.28M1.49B
Investing Cash Flow0-2.85B-3.33B-2.76B-1.95B-1.08B
Financing Cash Flow0-616.99M666.75M2.23B1.88B1.16B

AFC-HD AMS Life Science Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price835.00

Price Trends

50DMA851.50Negative
100DMA848.07Negative
200DMA847.76Negative

Market Momentum

MACD-3.49Positive
RSI42.07Neutral
STOCH57.29Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2927, the sentiment is Negative. The current price of 835.00 is below the 20-day moving average (MA) of 847.90, below the 50-day MA of 851.50, and below the 200-day MA of 847.76, indicating a bearish trend. The MACD of -3.49 indicates Positive momentum. The RSI at 42.07 is Neutral, neither overbought nor oversold. The STOCH value of 57.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2927.

AFC-HD AMS Life Science Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

JP:2927 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4526JP:452673OutperformJPY 86.65B16.13―2.89%3.68%-25.50%
JP:1375JP:137567NeutralJPY 45.58B11.68―2.10%6.19%363.19%
JP:3139JP:313966NeutralJPY 34.84B9.84―4.25%5.61%-15.32%
JP:2002JP:200265NeutralJPY 674.45B17.29―2.52%2.60%69.40%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
JP:2927JP:292762NeutralJPY 11.83B10.06―4.79%5.11%-19.41%
JP:2936JP:293655NeutralJPY 12.44B224.04――3.21%-90.33%

* Consumer Defensive Sector Average

Performance Comparison

-20%0%20%JP:2927JP:1375JP:2002JP:2936JP:3139JP:4526Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:2927 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:2927AFC-HD AMS Life Science Co., Ltd.835.0020.412.51%
JP:1375YUKIGUNI MAITAKE CO., LTD.1142.00145.2614.57%
JP:2002Nisshin Seifun Group Inc.2465.00674.9937.71%
JP:2936BASE FOOD Inc.233.00-101.00-30.24%
JP:3139Lacto Japan Co., Ltd.3480.0052.261.52%
JP:4526Riken Vitamin Co., Ltd.3800.001045.1137.94%

AFC-HD AMS Life Science Co., Ltd. Corporate Events

AFC-HD AMS Life Science Posts Higher Sales but Lower Profit for FY2026

Oct 15, 2026

AFC-HD AMS Life Science reported consolidated net sales of ¥34,324 million for the fiscal year ended August 31, 2026, a 5.1% increase from the previous year, supported by steady operating performance that lifted operating profit slightly to ¥2,455 mi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026